2022.09.13
I-Mab has successfully completed an EoP2 meeting with the CDE of China’s NMPA, and has obtained approval to initiate a Phase 3 registrational trial evaluating lemzoparlimab in combination with AZA for the first-line treatment of patients with newly diagnosed HR-MDS.
2022.09.10
I-Mab today announces encouraging data from its Phase 2 clinical trial of lemzoparlimab in combination with azacitidine in patients with newly diagnosed HR-MDS.
2022.09.06
I-Mab today announced that the results from its Phase 2 clinical study of lemzoparlimab in combination with azacitidine in patients with HR-MDS will be featured in a proffered paper presentation at the upcoming ESMO Congress 2022.
2022.08.30
I-Mab today announced financial results for the six months ended June 30, 2022, and provided key business updates.
2022.08.23
I-Mab today announced that it plans to implement share repurchases pursuant to the share repurchase program previously authorized by its Board of Directors.
2022.08.19
I-Mab will report business and corporate updates and financial results for the six months ended June 30, 2022, before the market opens on Tuesday, August 30, 2022.
2022.07.22
I-Mab today announced that the first patient in China has been treated with TJ-CD4B in a Phase 1 IMCT for patients with solid tumors.
2022.07.18
I-Mab today announced that it will present the latest Phase 2 clinical data of lemzoparlimab in combination with azacitidine in patients with higher risk myelodysplastic syndrome as a proffered paper at 2022 ESMO Congress.
2022.07.06
I-Mab today announced that it will host its 2022 Research and Development Day on July 20, 2022.
2022.06.23
I-Mab today announced that it was ranked among the top companies in five different categories by leading global financial publication Institutional Investor.